Sivia Capital Partners LLC Has $324,000 Holdings in Stryker Co. (NYSE:SYK)

Sivia Capital Partners LLC grew its position in Stryker Co. (NYSE:SYK) by 5.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 951 shares of the medical technology company’s stock after buying an additional 48 shares during the quarter. Sivia Capital Partners LLC’s holdings in Stryker were worth $324,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in SYK. Advisor OS LLC boosted its stake in Stryker by 6.4% in the 2nd quarter. Advisor OS LLC now owns 630 shares of the medical technology company’s stock worth $214,000 after purchasing an additional 38 shares during the period. North Star Asset Management Inc. lifted its holdings in shares of Stryker by 0.3% in the second quarter. North Star Asset Management Inc. now owns 99,177 shares of the medical technology company’s stock valued at $33,745,000 after purchasing an additional 305 shares in the last quarter. Private Advisor Group LLC boosted its position in shares of Stryker by 0.9% in the second quarter. Private Advisor Group LLC now owns 15,441 shares of the medical technology company’s stock worth $5,254,000 after buying an additional 131 shares during the period. New York Life Investment Management LLC grew its holdings in shares of Stryker by 0.8% during the second quarter. New York Life Investment Management LLC now owns 46,673 shares of the medical technology company’s stock valued at $15,880,000 after buying an additional 372 shares in the last quarter. Finally, Parkside Financial Bank & Trust raised its position in Stryker by 15.7% during the second quarter. Parkside Financial Bank & Trust now owns 974 shares of the medical technology company’s stock valued at $331,000 after buying an additional 132 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on SYK. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research note on Thursday, July 11th. Barclays upped their price objective on shares of Stryker from $374.00 to $402.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Stifel Nicolaus decreased their target price on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Needham & Company LLC upped their price target on shares of Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Finally, The Goldman Sachs Group started coverage on Stryker in a research report on Thursday, May 30th. They set a “neutral” rating and a $372.00 price objective for the company. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $377.11.

Stryker Trading Up 0.3 %

Shares of SYK stock opened at $358.92 on Friday. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $364.36. The company has a market cap of $136.78 billion, a PE ratio of 40.97, a price-to-earnings-growth ratio of 2.78 and a beta of 0.91. The company has a quick ratio of 0.95, a current ratio of 1.68 and a debt-to-equity ratio of 0.51. The business’s 50 day moving average is $339.06 and its two-hundred day moving average is $341.98.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. The business had revenue of $5.42 billion for the quarter, compared to analyst estimates of $5.40 billion. Stryker had a net margin of 16.12% and a return on equity of 22.89%. Stryker’s revenue was up 8.5% compared to the same quarter last year. During the same period last year, the business posted $2.54 EPS. Equities analysts predict that Stryker Co. will post 12 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.80 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 annualized dividend and a dividend yield of 0.89%. Stryker’s dividend payout ratio is presently 36.53%.

Insider Activity at Stryker

In other Stryker news, CFO Glenn S. Boehnlein sold 20,000 shares of Stryker stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total value of $6,660,000.00. Following the transaction, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at approximately $949,716. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Stryker news, CFO Glenn S. Boehnlein sold 20,000 shares of the firm’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total value of $6,660,000.00. Following the sale, the chief financial officer now directly owns 2,852 shares in the company, valued at approximately $949,716. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 190,000 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $323.46, for a total transaction of $61,457,400.00. Following the transaction, the director now directly owns 3,316,608 shares of the company’s stock, valued at approximately $1,072,790,023.68. The disclosure for this sale can be found here. Insiders sold a total of 210,600 shares of company stock worth $68,330,400 in the last 90 days. 5.90% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.